• “CBD may offer an option for treating different types of chronic pain,” reports Harvard article
• Topical CBD could help lower pain and inflammation due to arthritis, notes one study
• According to Simply Sonoma, the inflammation market represents a $100-billion opportunity and is one of three areas the company is working in

CBD, or cannabidiol, the second most prevalent of the active ingredients of cannabis, is gaining attention as a potential effective therapy for many uses, including inflammation. A recent article from Harvard Health Publishing notes the progress being made in that area (https://ibn.fm/xlwDr), an area that Simply Sonoma is heavily focused on.

“CBD stands for cannabidiol,” the article stated. “It is the second most prevalent of the active ingredients of cannabis (marijuana). While CBD is an essential component of medical marijuana, it is derived directly from the hemp plant, which is a cousin of the marijuana plant. While CBD is a component of marijuana (one of hundreds), by itself it does not cause a ‘high.’ According to a report from the World Health Organization, ‘In humans, CBD exhibits no effects indicative of any abuse or dependence potential. . . . To date, there is no evidence of public health-related problems associated with the use of pure CBD.’

“CBD may offer an option for addressing different types of chronic pain. A study from the ‘European Journal of Pain’ showed, using an animal model, CBD applied on the skin could help lower pain and inflammation due to arthritis,” the article continued. “Another study demonstrated the mechanism by which CBD inhibits inflammatory and neuropathic pain, two of the most difficult types of chronic pain to treat. More study in humans is needed in this area to substantiate the claims of CBD proponents about pain control.”

According to Allied Market Research, the global pain management and inflammation market is expected to reach nearly $92 million dollars by 2027 and is one of three areas the company is working in; the other two are sleep aids, a $71-billion market, and the gut and probiotic health market, $54.77 billion in 2020. Simply Sonoma’s product development consists of clean, organic ingredients combined with a solar-first approach, resulting in as close to zero C02 emissions as possible. The company is currently working on an array of new products, including a joint/pain cream, as well as a nonalcoholic beverage made from grapes grown in Sonoma County.

Simply Sonoma, a CBD company focused on building a reputation as a leader in plant-based medicinal health and beauty products. Specifically, Sonoma is developing broad-spectrum CBD products for therapeutic applications from a scientific perspective. Its products come from the farm rather than from a lab, with the goal of achieving fewer side effects and more efficacy for patients. The company is committed to incorporating published, science-based trials and research into the formulation and manufacture of its CBD offerings.

“At Simply Sonoma, we strive to create the best organically grown medicinal products,” the company states. “We’re creating unique medicinal hemp strains that are alternatives and supplements to traditional, chemically manufactured therapies. We believe in all-natural, organically sun-grown, plant-based medicinals. We provide consumers with science-based education on CBD for disease and lifestyle needs. In our commitment to minimize our carbon footprint, we are powering our operations off the grid with solar.”

Simply Sonoma is a different kind of natural company and looks forward to introducing its exceptional products to the consumer market. 

For more information, or to invest in Simply Sonoma, visit the company’s website at www.SimplySonoma.org.

NOTE TO INVESTORS: The latest news and updates relating to Simply Sonoma are available in the company’s newsroom at https://ibn.fm/Sonoma

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.